clinical trial · NCT06363994
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
InnoCare Pharma Inc.·phase3·recruiting·n = 476
Mantle Cell LymphomaOrelabrutinibBendamustine InjectionRituximabOrelabrutinib Placebo
brief summary
Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)
started
May 29, 2024
primary completion
Jun 25, 2031
completion
Jun 25, 2032
last updated
Dec 27, 2024
official title
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) Vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol